The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment With Placebo Using Improvement PRAM Score as a Primary Outcome

• Status: Not yet recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Our study aiming to look in improvement of Pediatric Respiratory Assessment Measure (PRAM) score as a primary outcome. The secondary outcomes involving the need for second step management, need for admission and possible side effects.

It's double blinded randomized control study comparing Nebulized Epinephrine with standard treatment (salbutamol + Ipratropium) versus the standard treatment only in pediatric patient.

A pilot study will be conducted before to detect the sample size required and data will be collected at deferent interval post treatment targeting intension to treat for analysis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oman Medical Speciality Board
• Treatments: Epinephrine

Criteria

Inclusion Criteria:

• Age between 3 and 13 years old

• Pre-existing diagnosis of asthma

• Presenting to the ED with an asthma exacerbation

Exclusion Criteria:

• History of chronic lung or upper airway disease other than asthma

• History significant, uncorrected congenital heart disease or cardiac arrhythmia

• Impending respiratory failure

• Allergy to epinephrine